Print Page     Close Window     

Investor Home

Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied for the treatment of moderate to severe CABP. We have completed the LEAP 1 Phase 3 trial ... More >>

Recent Newsmore >
09/28/17
Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will showcase data at ID Week 2017 taking place from October 4-8 in San Diego, California. At the meeting, three presentations will feature the company’s m... 
09/20/17
Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Chief Executive Officer Colin Broom, M.D., will provide a company overview, including the previously released lefamulin evaluation against pneumonia (LEAP 1) Phase 3 trial topline results, a... 
09/19/17
Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share. In addition, Nabriva Therapeutics has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,411,764 ordinary shares at the public offering price, less the underwriting discounts and commissions. All of t... 
Upcoming Eventsmore >
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.